Company Performance Metrics
- Will West: CEOPast Role: Cancer Targeting Systems, President & CEO
- Celia Economides: Chief Financial Officer and Chief Business OfficerPast Role: Gritstone bio, interim Chief Executive Officer
CellCentric is a clinical-stage biotechnology company focused on developing small molecule therapies for cancer treatment. The company researches epigenetic and transcription-related mechanisms involved in tumor growth and applies this work to the development of targeted oncology therapeutics. Its lead drug candidate, inobrodib, is an oral
p300/CBP inhibitor being evaluated for multiple myeloma and other hematologic and solid tumor indications.
CellCentric conducts activities across drug discovery, medicinal chemistry, translational research, and clinical development through collaborations with research institutions and clinical partners. The company also develops intellectual property and therapeutic programs related to chromatin regulation and gene expression in cancer biology. Its research platform is designed to identify and advance therapies targeting cancer-driving transcription pathways and epigenetic regulators.
